JP2005518371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005518371A5 JP2005518371A5 JP2003550753A JP2003550753A JP2005518371A5 JP 2005518371 A5 JP2005518371 A5 JP 2005518371A5 JP 2003550753 A JP2003550753 A JP 2003550753A JP 2003550753 A JP2003550753 A JP 2003550753A JP 2005518371 A5 JP2005518371 A5 JP 2005518371A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- haloalkyl
- membered
- substituted
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 3230
- 125000005843 halogen group Chemical group 0.000 claims 340
- 229910052760 oxygen Inorganic materials 0.000 claims 312
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 288
- 125000004093 cyano group Chemical group *C#N 0.000 claims 281
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 279
- 229920006395 saturated elastomer Polymers 0.000 claims 235
- 229910052717 sulfur Inorganic materials 0.000 claims 221
- 125000004429 atom Chemical group 0.000 claims 218
- 229910052799 carbon Inorganic materials 0.000 claims 218
- 125000001424 substituent group Chemical group 0.000 claims 191
- 150000001875 compounds Chemical class 0.000 claims 175
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 129
- 229910052757 nitrogen Inorganic materials 0.000 claims 126
- 125000001188 haloalkyl group Chemical group 0.000 claims 124
- -1 3-nitrophenyl Chemical group 0.000 claims 116
- 229910052739 hydrogen Inorganic materials 0.000 claims 105
- 125000004432 carbon atom Chemical group C* 0.000 claims 83
- 125000004430 oxygen atom Chemical group O* 0.000 claims 82
- 125000004434 sulfur atom Chemical group 0.000 claims 82
- 125000000623 heterocyclic group Chemical group 0.000 claims 80
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims 72
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 69
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 58
- 125000004043 oxo group Chemical group O=* 0.000 claims 56
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 55
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 50
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 40
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 38
- 125000002619 bicyclic group Chemical group 0.000 claims 34
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 34
- 150000001721 carbon Chemical group 0.000 claims 33
- 125000005842 heteroatom Chemical group 0.000 claims 31
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 claims 30
- 125000002950 monocyclic group Chemical group 0.000 claims 29
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 20
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 claims 15
- 230000002757 inflammatory effect Effects 0.000 claims 15
- 125000001624 naphthyl group Chemical group 0.000 claims 13
- JWPMHRXIIOEZRU-UHFFFAOYSA-N 2,5-dihydro-1,2,4-thiadiazole Chemical compound C1NC=NS1 JWPMHRXIIOEZRU-UHFFFAOYSA-N 0.000 claims 12
- 208000004454 Hyperalgesia Diseases 0.000 claims 12
- 208000002193 Pain Diseases 0.000 claims 12
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 12
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 11
- 125000005605 benzo group Chemical group 0.000 claims 11
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 10
- HBJUQLMVCIEESP-UHFFFAOYSA-N 2,5-dihydro-1,2,4-oxadiazole Chemical compound C1NC=NO1 HBJUQLMVCIEESP-UHFFFAOYSA-N 0.000 claims 9
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 9
- 208000004296 neuralgia Diseases 0.000 claims 9
- 208000021722 neuropathic pain Diseases 0.000 claims 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 9
- 230000002792 vascular Effects 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 230000002496 gastric effect Effects 0.000 claims 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 6
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 claims 6
- JRLFRFTXXMZSND-UHFFFAOYSA-N 1,2,4-triazoline Chemical compound C1NNC=N1 JRLFRFTXXMZSND-UHFFFAOYSA-N 0.000 claims 6
- QYMGRIFMUQCAJW-UHFFFAOYSA-N 1,2-dihydropyrazine Chemical compound C1NC=CN=C1 QYMGRIFMUQCAJW-UHFFFAOYSA-N 0.000 claims 6
- RMQOXNXLVICLNK-UHFFFAOYSA-N 1,4-dihydro-1,3,5-triazine Chemical compound C1NC=NC=N1 RMQOXNXLVICLNK-UHFFFAOYSA-N 0.000 claims 6
- PNJBXRVMRQIFKK-UHFFFAOYSA-N 1,4-dihydrotriazine Chemical compound C1C=CNN=N1 PNJBXRVMRQIFKK-UHFFFAOYSA-N 0.000 claims 6
- LOZWAPSEEHRYPG-UHFFFAOYSA-N 1,4-dithiane Chemical compound C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 claims 6
- CQHHFSBXAPCQFG-UHFFFAOYSA-N 2,3-dihydro-1,2,4-oxadiazole Chemical compound C1NOC=N1 CQHHFSBXAPCQFG-UHFFFAOYSA-N 0.000 claims 6
- ALBVNKOEWADZPF-UHFFFAOYSA-N 2,3-dihydro-1,2,4-thiadiazole Chemical compound C1NSC=N1 ALBVNKOEWADZPF-UHFFFAOYSA-N 0.000 claims 6
- IIATVLXXAYLQIZ-UHFFFAOYSA-N 2,5-dihydro-1,2,4-triazine Chemical compound C1C=NNC=N1 IIATVLXXAYLQIZ-UHFFFAOYSA-N 0.000 claims 6
- KWIVRAVCZJXOQC-UHFFFAOYSA-N 3h-oxathiazole Chemical compound N1SOC=C1 KWIVRAVCZJXOQC-UHFFFAOYSA-N 0.000 claims 6
- 208000035154 Hyperesthesia Diseases 0.000 claims 6
- 206010065390 Inflammatory pain Diseases 0.000 claims 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 6
- 206010053552 allodynia Diseases 0.000 claims 6
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 claims 6
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 6
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 claims 5
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims 4
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 claims 4
- USSYLANTAAUELR-UHFFFAOYSA-N 1,2-dihydro-1,2,4-triazine Chemical compound N1NC=NC=C1 USSYLANTAAUELR-UHFFFAOYSA-N 0.000 claims 4
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims 4
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 4
- 230000005856 abnormality Effects 0.000 claims 4
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims 4
- PPSZHCXTGRHULJ-UHFFFAOYSA-N dioxazine Chemical compound O1ON=CC=C1 PPSZHCXTGRHULJ-UHFFFAOYSA-N 0.000 claims 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 4
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 claims 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 3
- OQJVXNHMUWQQEW-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrazine Chemical compound C1CNC=CN1 OQJVXNHMUWQQEW-UHFFFAOYSA-N 0.000 claims 3
- JQIZHNLEFQMDCQ-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridazine Chemical compound C1CC=CNN1 JQIZHNLEFQMDCQ-UHFFFAOYSA-N 0.000 claims 3
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 claims 3
- JZTKNVMVUVSGJF-UHFFFAOYSA-N 1,2,3,5-oxatriazole Chemical compound C=1N=NON=1 JZTKNVMVUVSGJF-UHFFFAOYSA-N 0.000 claims 3
- XLEDBLKSWOYHES-UHFFFAOYSA-N 1,2,3,5-thiatriazole Chemical compound C=1N=NSN=1 XLEDBLKSWOYHES-UHFFFAOYSA-N 0.000 claims 3
- IOLQWFQLCNMKAZ-UHFFFAOYSA-N 1,2,3,6-tetrahydropyrazine Chemical compound C1CN=CCN1 IOLQWFQLCNMKAZ-UHFFFAOYSA-N 0.000 claims 3
- WNSPCCWAAVHWIM-UHFFFAOYSA-N 1,2,3,6-tetrahydropyridazine Chemical compound C1NNCC=C1 WNSPCCWAAVHWIM-UHFFFAOYSA-N 0.000 claims 3
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 claims 3
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims 3
- BLWJJPNXUDWVCG-UHFFFAOYSA-N 1,2,4-oxadiazolidine Chemical compound C1NCON1 BLWJJPNXUDWVCG-UHFFFAOYSA-N 0.000 claims 3
- YFCCVJQVYQHMOG-UHFFFAOYSA-N 1,2,4-thiadiazolidine Chemical compound C1NCSN1 YFCCVJQVYQHMOG-UHFFFAOYSA-N 0.000 claims 3
- WNBQDDAKLKODPH-UHFFFAOYSA-N 1,2,4-triazolidine Chemical compound C1NCNN1 WNBQDDAKLKODPH-UHFFFAOYSA-N 0.000 claims 3
- OHFXUPDPPRJZES-UHFFFAOYSA-N 1,2,5,6-tetrahydropyrimidine Chemical compound C1CC=NCN1 OHFXUPDPPRJZES-UHFFFAOYSA-N 0.000 claims 3
- BKWQKVJYXODDAC-UHFFFAOYSA-N 1,2-dihydropyridazine Chemical compound N1NC=CC=C1 BKWQKVJYXODDAC-UHFFFAOYSA-N 0.000 claims 3
- MMWRGWQTAMNAFC-UHFFFAOYSA-N 1,2-dihydropyridine Chemical compound C1NC=CC=C1 MMWRGWQTAMNAFC-UHFFFAOYSA-N 0.000 claims 3
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 claims 3
- NTSJGNVMDZAPJE-UHFFFAOYSA-N 1,2-dihydrotriazine Chemical compound N1NN=CC=C1 NTSJGNVMDZAPJE-UHFFFAOYSA-N 0.000 claims 3
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 claims 3
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 claims 3
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 claims 3
- SKLDBJVFTOQKHE-UHFFFAOYSA-N 1,3,4-oxadiazolidine Chemical compound C1NNCO1 SKLDBJVFTOQKHE-UHFFFAOYSA-N 0.000 claims 3
- NWEFQXYVAUNGNI-UHFFFAOYSA-N 1,3,4-oxathiazolidine Chemical compound C1NSCO1 NWEFQXYVAUNGNI-UHFFFAOYSA-N 0.000 claims 3
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 claims 3
- BRQBVEHLEITSPT-UHFFFAOYSA-N 1,3,4-thiadiazolidine Chemical compound C1NNCS1 BRQBVEHLEITSPT-UHFFFAOYSA-N 0.000 claims 3
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 claims 3
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 3
- UKOMUVPFRFPHDS-UHFFFAOYSA-N 1,4,2-dioxazine Chemical compound O1C=CON=C1 UKOMUVPFRFPHDS-UHFFFAOYSA-N 0.000 claims 3
- DDGWEFMIIOIMEF-UHFFFAOYSA-N 1,4,2-dithiazine Chemical compound S1C=CSN=C1 DDGWEFMIIOIMEF-UHFFFAOYSA-N 0.000 claims 3
- FMYSHKHSQFXYRS-UHFFFAOYSA-N 1,4,2-oxathiazine Chemical compound O1C=CSC=N1 FMYSHKHSQFXYRS-UHFFFAOYSA-N 0.000 claims 3
- GWOPJRXEMFYVQP-UHFFFAOYSA-N 1,4,2-oxathiazolidine Chemical compound C1NOCS1 GWOPJRXEMFYVQP-UHFFFAOYSA-N 0.000 claims 3
- BGMLUCPALPKNOV-UHFFFAOYSA-N 1,4,5,6-tetrahydropyridazine Chemical compound C1CNN=CC1 BGMLUCPALPKNOV-UHFFFAOYSA-N 0.000 claims 3
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 3
- KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 claims 3
- XYNBEQAWBCGIMD-UHFFFAOYSA-N 1,4-dihydropyrazine Chemical compound N1C=CNC=C1 XYNBEQAWBCGIMD-UHFFFAOYSA-N 0.000 claims 3
- HZVGMPJZVYBYEK-UHFFFAOYSA-N 1,4-dihydropyridazine Chemical compound C1C=CNN=C1 HZVGMPJZVYBYEK-UHFFFAOYSA-N 0.000 claims 3
- OKGNMRKOGWTADH-UHFFFAOYSA-N 1,4-dihydropyrimidine Chemical compound C1C=CNC=N1 OKGNMRKOGWTADH-UHFFFAOYSA-N 0.000 claims 3
- AKAIWNDBVZJOAJ-UHFFFAOYSA-N 1,4-dithiine Chemical compound S1C=CSC=C1 AKAIWNDBVZJOAJ-UHFFFAOYSA-N 0.000 claims 3
- JBYHSSAVUBIJMK-UHFFFAOYSA-N 1,4-oxathiane Chemical compound C1CSCCO1 JBYHSSAVUBIJMK-UHFFFAOYSA-N 0.000 claims 3
- CPRVXMQHLPTWLY-UHFFFAOYSA-N 1,4-oxathiine Chemical compound O1C=CSC=C1 CPRVXMQHLPTWLY-UHFFFAOYSA-N 0.000 claims 3
- QFXRFFKVJYBGLQ-UHFFFAOYSA-N 1,6-dihydro-1,2,4-triazine Chemical compound C1NN=CN=C1 QFXRFFKVJYBGLQ-UHFFFAOYSA-N 0.000 claims 3
- ZEFGUWRQFNTGGX-UHFFFAOYSA-N 1,6-dihydropyridazine Chemical compound C1NN=CC=C1 ZEFGUWRQFNTGGX-UHFFFAOYSA-N 0.000 claims 3
- DWKUKQRKVCMOLP-UHFFFAOYSA-N 1-piperideine Chemical compound C1CCN=CC1 DWKUKQRKVCMOLP-UHFFFAOYSA-N 0.000 claims 3
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims 3
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 claims 3
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 claims 3
- GRYYTSJXIFGRAL-UHFFFAOYSA-N 2,3-dihydro-1,2,4-triazine Chemical compound C1NN=CC=N1 GRYYTSJXIFGRAL-UHFFFAOYSA-N 0.000 claims 3
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 claims 3
- YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical compound C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 claims 3
- RZQQXRVPPOOCQR-UHFFFAOYSA-N 2,3-dihydro-1,3,4-oxadiazole Chemical compound C1NN=CO1 RZQQXRVPPOOCQR-UHFFFAOYSA-N 0.000 claims 3
- VKRGLHLCUMMXHA-UHFFFAOYSA-N 2,3-dihydro-1,3,4-thiadiazole Chemical compound C1NN=CS1 VKRGLHLCUMMXHA-UHFFFAOYSA-N 0.000 claims 3
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 claims 3
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 claims 3
- AXYMXGSRCWCVIK-UHFFFAOYSA-N 2,3-dihydro-1,4,2-dioxazine Chemical compound C1NOC=CO1 AXYMXGSRCWCVIK-UHFFFAOYSA-N 0.000 claims 3
- RTQGSDHQFAONPG-UHFFFAOYSA-N 2,3-dihydro-1,4,3-oxathiazine Chemical compound C1NSC=CO1 RTQGSDHQFAONPG-UHFFFAOYSA-N 0.000 claims 3
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 claims 3
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 claims 3
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims 3
- WUCWFMVYIKMAPG-UHFFFAOYSA-N 2,3-dihydropyrazine Chemical compound C1CN=CC=N1 WUCWFMVYIKMAPG-UHFFFAOYSA-N 0.000 claims 3
- NZHIIDNOLFOHSG-UHFFFAOYSA-N 2,3-dihydropyridine Chemical compound C1CN=CC=C1 NZHIIDNOLFOHSG-UHFFFAOYSA-N 0.000 claims 3
- NHZLLKNRTDIFAD-UHFFFAOYSA-N 2,5-dihydro-1,3-oxazole Chemical compound C1OCN=C1 NHZLLKNRTDIFAD-UHFFFAOYSA-N 0.000 claims 3
- JLPUISACQXFVRC-UHFFFAOYSA-N 2,5-dihydro-1,3-thiazole Chemical compound C1SCN=C1 JLPUISACQXFVRC-UHFFFAOYSA-N 0.000 claims 3
- FFMBYMANYCDCMK-UHFFFAOYSA-N 2,5-dihydro-1h-imidazole Chemical compound C1NCN=C1 FFMBYMANYCDCMK-UHFFFAOYSA-N 0.000 claims 3
- SYOANZBNGDEJFH-UHFFFAOYSA-N 2,5-dihydro-1h-triazole Chemical compound C1NNN=C1 SYOANZBNGDEJFH-UHFFFAOYSA-N 0.000 claims 3
- BNDCYQXUFIHUHS-UHFFFAOYSA-N 2,5-dihydropyrazine Chemical compound C1C=NCC=N1 BNDCYQXUFIHUHS-UHFFFAOYSA-N 0.000 claims 3
- WRLAXLNSBDVNRL-UHFFFAOYSA-N 2,5-dihydropyrimidine Chemical compound C1C=NCN=C1 WRLAXLNSBDVNRL-UHFFFAOYSA-N 0.000 claims 3
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 claims 3
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 claims 3
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims 3
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims 3
- HCNVXDPRTRLNFX-UHFFFAOYSA-N 2h-1,3,4-oxadiazine Chemical compound C1OC=CN=N1 HCNVXDPRTRLNFX-UHFFFAOYSA-N 0.000 claims 3
- KLVQAIJZDCCJRZ-UHFFFAOYSA-N 2h-1,3,4-thiadiazine Chemical compound C1SC=CN=N1 KLVQAIJZDCCJRZ-UHFFFAOYSA-N 0.000 claims 3
- PZOJXKYWPGPWQC-UHFFFAOYSA-N 2h-1,3,5-oxadiazine Chemical compound C1OC=NC=N1 PZOJXKYWPGPWQC-UHFFFAOYSA-N 0.000 claims 3
- VNXIZDXJEGBXRQ-UHFFFAOYSA-N 2h-1,3,5-thiadiazine Chemical compound C1SC=NC=N1 VNXIZDXJEGBXRQ-UHFFFAOYSA-N 0.000 claims 3
- KGWNRZLPXLBMPS-UHFFFAOYSA-N 2h-1,3-oxazine Chemical compound C1OC=CC=N1 KGWNRZLPXLBMPS-UHFFFAOYSA-N 0.000 claims 3
- NTYABNDBNKVWOO-UHFFFAOYSA-N 2h-1,3-thiazine Chemical compound C1SC=CC=N1 NTYABNDBNKVWOO-UHFFFAOYSA-N 0.000 claims 3
- YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 claims 3
- ZAISDHPZTZIFQF-UHFFFAOYSA-N 2h-1,4-thiazine Chemical compound C1SC=CN=C1 ZAISDHPZTZIFQF-UHFFFAOYSA-N 0.000 claims 3
- QMDFJHAAWUGVKQ-UHFFFAOYSA-N 2h-thiopyran Chemical compound C1SC=CC=C1 QMDFJHAAWUGVKQ-UHFFFAOYSA-N 0.000 claims 3
- LIYUKZAZFWIJPB-UHFFFAOYSA-N 3,4-dihydro-2h-1,3,4-thiadiazine Chemical compound C1NNC=CS1 LIYUKZAZFWIJPB-UHFFFAOYSA-N 0.000 claims 3
- GNNHQRGDLMQALS-UHFFFAOYSA-N 3,4-dihydro-2h-1,3,5-thiadiazine Chemical compound C1NCN=CS1 GNNHQRGDLMQALS-UHFFFAOYSA-N 0.000 claims 3
- NLXFKDHULKLENC-UHFFFAOYSA-N 3,4-dihydro-2h-1,3-oxazine Chemical compound C1NCC=CO1 NLXFKDHULKLENC-UHFFFAOYSA-N 0.000 claims 3
- BOLMDIXLULGTBD-UHFFFAOYSA-N 3,4-dihydro-2h-oxazine Chemical compound C1CC=CON1 BOLMDIXLULGTBD-UHFFFAOYSA-N 0.000 claims 3
- NWWJFMCCTZLKNT-UHFFFAOYSA-N 3,4-dihydro-2h-thiazine Chemical compound C1CC=CSN1 NWWJFMCCTZLKNT-UHFFFAOYSA-N 0.000 claims 3
- ATVJJNGVPSKBGO-UHFFFAOYSA-N 3,4-dihydro-2h-thiopyran Chemical compound C1CSC=CC1 ATVJJNGVPSKBGO-UHFFFAOYSA-N 0.000 claims 3
- RDOAUPPSCNSYPM-UHFFFAOYSA-N 3,4-dihydropyridine Chemical compound C1CC=NC=C1 RDOAUPPSCNSYPM-UHFFFAOYSA-N 0.000 claims 3
- LPHWCAUEPAUFHZ-UHFFFAOYSA-N 3,6-Dihydropyridine Chemical compound C1C=CCN=C1 LPHWCAUEPAUFHZ-UHFFFAOYSA-N 0.000 claims 3
- MUYVJODFVRCAOF-UHFFFAOYSA-N 3,6-dihydro-1,2,4-triazine Chemical compound C1C=NCN=N1 MUYVJODFVRCAOF-UHFFFAOYSA-N 0.000 claims 3
- YFGWHNJRWZLMPC-UHFFFAOYSA-N 3,6-dihydro-2h-1,2,5-thiadiazine Chemical compound C1NSCN=C1 YFGWHNJRWZLMPC-UHFFFAOYSA-N 0.000 claims 3
- AMKVFOFJZLHHDC-UHFFFAOYSA-N 3,6-dihydro-2h-1,3,4-thiadiazine Chemical compound C1NN=CCS1 AMKVFOFJZLHHDC-UHFFFAOYSA-N 0.000 claims 3
- GPAZGRQYFCWGOO-UHFFFAOYSA-N 3,6-dihydro-2h-1,3,5-thiadiazine Chemical compound C1NC=NCS1 GPAZGRQYFCWGOO-UHFFFAOYSA-N 0.000 claims 3
- RUPLWPYHVWSFEF-UHFFFAOYSA-N 3,6-dihydro-2h-1,3-oxazine Chemical compound C1NC=CCO1 RUPLWPYHVWSFEF-UHFFFAOYSA-N 0.000 claims 3
- DNUJVGBNIXGTHC-UHFFFAOYSA-N 3,6-dihydro-2h-oxazine Chemical compound C1NOCC=C1 DNUJVGBNIXGTHC-UHFFFAOYSA-N 0.000 claims 3
- SGDYNMJTXCTTAF-UHFFFAOYSA-N 3,6-dihydro-2h-thiazine Chemical compound C1NSCC=C1 SGDYNMJTXCTTAF-UHFFFAOYSA-N 0.000 claims 3
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 claims 3
- GUUULVAMQJLDSY-UHFFFAOYSA-N 4,5-dihydro-1,2-thiazole Chemical compound C1CC=NS1 GUUULVAMQJLDSY-UHFFFAOYSA-N 0.000 claims 3
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 claims 3
- BKYIMUSAVMSMGK-UHFFFAOYSA-N 4,5-dihydropyridazine Chemical compound C1CC=NN=C1 BKYIMUSAVMSMGK-UHFFFAOYSA-N 0.000 claims 3
- BBZZGDLNBVRFFI-UHFFFAOYSA-N 4,5-dihydropyrimidine Chemical compound C1CN=CN=C1 BBZZGDLNBVRFFI-UHFFFAOYSA-N 0.000 claims 3
- ZTPBNDYYCCGCGD-UHFFFAOYSA-N 4,5-dihydrotriazine Chemical compound C1CN=NN=C1 ZTPBNDYYCCGCGD-UHFFFAOYSA-N 0.000 claims 3
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 3
- MRUWJENAYHTDQG-UHFFFAOYSA-N 4H-pyran Chemical compound C1C=COC=C1 MRUWJENAYHTDQG-UHFFFAOYSA-N 0.000 claims 3
- NGUCKHVSIWZIPQ-UHFFFAOYSA-N 4h-1,2,5-oxadiazine Chemical compound C1C=NOC=N1 NGUCKHVSIWZIPQ-UHFFFAOYSA-N 0.000 claims 3
- QBMIYRSEKPGOJY-UHFFFAOYSA-N 4h-1,3,4-oxadiazine Chemical compound N1C=COC=N1 QBMIYRSEKPGOJY-UHFFFAOYSA-N 0.000 claims 3
- AVHCHJKMIGPLIZ-UHFFFAOYSA-N 4h-1,3,4-thiadiazine Chemical compound N1C=CSC=N1 AVHCHJKMIGPLIZ-UHFFFAOYSA-N 0.000 claims 3
- LPWMFGGUZLCGBF-UHFFFAOYSA-N 4h-1,3,5-oxadiazine Chemical compound C1N=COC=N1 LPWMFGGUZLCGBF-UHFFFAOYSA-N 0.000 claims 3
- QLOAZIIJBGXVDN-UHFFFAOYSA-N 4h-1,3,5-thiadiazine Chemical compound C1N=CSC=N1 QLOAZIIJBGXVDN-UHFFFAOYSA-N 0.000 claims 3
- UOSQFVCDJBZRKS-UHFFFAOYSA-N 4h-1,4-oxazine Chemical compound N1C=COC=C1 UOSQFVCDJBZRKS-UHFFFAOYSA-N 0.000 claims 3
- ZOXMLSDKXHNVOQ-UHFFFAOYSA-N 4h-1,4-thiazine Chemical compound N1C=CSC=C1 ZOXMLSDKXHNVOQ-UHFFFAOYSA-N 0.000 claims 3
- BMRPOOWUTVUBRI-UHFFFAOYSA-N 4h-oxazine Chemical compound C1C=CON=C1 BMRPOOWUTVUBRI-UHFFFAOYSA-N 0.000 claims 3
- XZMWWZZCMGYPHD-UHFFFAOYSA-N 4h-thiazine Chemical compound C1C=CSN=C1 XZMWWZZCMGYPHD-UHFFFAOYSA-N 0.000 claims 3
- STBGWNRZMPCVTG-UHFFFAOYSA-N 4h-thiopyran Chemical compound C1C=CSC=C1 STBGWNRZMPCVTG-UHFFFAOYSA-N 0.000 claims 3
- VNOMHCXUKPUGJE-UHFFFAOYSA-N 5,6-dihydro-1,2,4-triazine Chemical compound C1CN=NC=N1 VNOMHCXUKPUGJE-UHFFFAOYSA-N 0.000 claims 3
- SGVDPBAZOBRHRE-UHFFFAOYSA-N 5,6-dihydro-1,4,2-dithiazine Chemical compound C1CSN=CS1 SGVDPBAZOBRHRE-UHFFFAOYSA-N 0.000 claims 3
- VXBRQDSRTRLHPJ-UHFFFAOYSA-N 5,6-dihydro-1,4,2-oxathiazine Chemical compound C1CSC=NO1 VXBRQDSRTRLHPJ-UHFFFAOYSA-N 0.000 claims 3
- QUJTVGHTSQMUMV-UHFFFAOYSA-N 5,6-dihydro-1,4,3-oxathiazine Chemical compound C1CSN=CO1 QUJTVGHTSQMUMV-UHFFFAOYSA-N 0.000 claims 3
- OWKSGFQMLODDJJ-UHFFFAOYSA-N 5,6-dihydro-2h-1,2,5-thiadiazine Chemical compound C1NC=CNS1 OWKSGFQMLODDJJ-UHFFFAOYSA-N 0.000 claims 3
- UFTHEDBYLPFRDP-UHFFFAOYSA-N 5,6-dihydro-2h-oxazine Chemical compound C1CC=CNO1 UFTHEDBYLPFRDP-UHFFFAOYSA-N 0.000 claims 3
- MXDHUJDGSBTOTI-UHFFFAOYSA-N 5,6-dihydro-2h-thiadiazine Chemical compound C1CC=NNS1 MXDHUJDGSBTOTI-UHFFFAOYSA-N 0.000 claims 3
- MSTFRUQNYRRUKZ-UHFFFAOYSA-N 5,6-dihydro-2h-thiazine Chemical compound C1CC=CNS1 MSTFRUQNYRRUKZ-UHFFFAOYSA-N 0.000 claims 3
- OXHGKAXWARAOPZ-UHFFFAOYSA-N 5,6-dihydro-4h-1,2,5-thiadiazine Chemical compound C1NCC=NS1 OXHGKAXWARAOPZ-UHFFFAOYSA-N 0.000 claims 3
- ZQNUENDKDTXKSU-UHFFFAOYSA-N 5,6-dihydro-4h-1,3,4-thiadiazine Chemical compound C1CSC=NN1 ZQNUENDKDTXKSU-UHFFFAOYSA-N 0.000 claims 3
- YWOIQIYQBRDOQA-UHFFFAOYSA-N 5,6-dihydro-4h-1,3-oxazine Chemical compound C1COC=NC1 YWOIQIYQBRDOQA-UHFFFAOYSA-N 0.000 claims 3
- BYVSMDBDTBXASR-UHFFFAOYSA-N 5,6-dihydro-4h-oxazine Chemical compound C1CON=CC1 BYVSMDBDTBXASR-UHFFFAOYSA-N 0.000 claims 3
- WSXNRJXPTNQJBH-UHFFFAOYSA-N 5,6-dihydro-4h-thiazine Chemical compound C1CSN=CC1 WSXNRJXPTNQJBH-UHFFFAOYSA-N 0.000 claims 3
- MIOUOWAIZBEKFY-UHFFFAOYSA-N 6h-1,2,5-oxadiazine Chemical compound C1ON=CC=N1 MIOUOWAIZBEKFY-UHFFFAOYSA-N 0.000 claims 3
- BMZKZBWPMWEQAY-UHFFFAOYSA-N 6h-1,2,5-thiadiazine Chemical compound C1SN=CC=N1 BMZKZBWPMWEQAY-UHFFFAOYSA-N 0.000 claims 3
- BTSRCKGXYLBFOS-UHFFFAOYSA-N 6h-1,3,4-oxadiazine Chemical compound C1OC=NN=C1 BTSRCKGXYLBFOS-UHFFFAOYSA-N 0.000 claims 3
- BJZFKUQYNPYBGE-UHFFFAOYSA-N 6h-1,3,4-thiadiazine Chemical compound C1SC=NN=C1 BJZFKUQYNPYBGE-UHFFFAOYSA-N 0.000 claims 3
- GMLMFZXBPRIXPK-UHFFFAOYSA-N 6h-1,3-oxazine Chemical compound C1OC=NC=C1 GMLMFZXBPRIXPK-UHFFFAOYSA-N 0.000 claims 3
- VNCVSCGVODHWLX-UHFFFAOYSA-N 6h-1,3-thiazine Chemical compound C1SC=NC=C1 VNCVSCGVODHWLX-UHFFFAOYSA-N 0.000 claims 3
- QFPDHKBNCJAOKJ-UHFFFAOYSA-N 6h-oxazine Chemical compound C1ON=CC=C1 QFPDHKBNCJAOKJ-UHFFFAOYSA-N 0.000 claims 3
- DLNUKTLHURJVDF-UHFFFAOYSA-N 6h-thiazine Chemical compound C1SN=CC=C1 DLNUKTLHURJVDF-UHFFFAOYSA-N 0.000 claims 3
- CCVRDKFBCDVQBY-UHFFFAOYSA-N C1NC=CN=N1 Chemical compound C1NC=CN=N1 CCVRDKFBCDVQBY-UHFFFAOYSA-N 0.000 claims 3
- 208000006561 Cluster Headache Diseases 0.000 claims 3
- 206010012434 Dermatitis allergic Diseases 0.000 claims 3
- 206010012735 Diarrhoea Diseases 0.000 claims 3
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims 3
- 208000002111 Eye Abnormalities Diseases 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 206010019233 Headaches Diseases 0.000 claims 3
- 208000009889 Herpes Simplex Diseases 0.000 claims 3
- 206010020853 Hypertonic bladder Diseases 0.000 claims 3
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 206010028851 Necrosis Diseases 0.000 claims 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 3
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 3
- 208000003251 Pruritus Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 3
- 208000025747 Rheumatic disease Diseases 0.000 claims 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- 206010043269 Tension headache Diseases 0.000 claims 3
- 208000008548 Tension-Type Headache Diseases 0.000 claims 3
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 claims 3
- 208000025865 Ulcer Diseases 0.000 claims 3
- 206010047642 Vitiligo Diseases 0.000 claims 3
- 206010052428 Wound Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 208000005298 acute pain Diseases 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 208000018912 cluster headache syndrome Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 208000000718 duodenal ulcer Diseases 0.000 claims 3
- 210000000981 epithelium Anatomy 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 230000003779 hair growth Effects 0.000 claims 3
- 231100000869 headache Toxicity 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims 3
- 230000004968 inflammatory condition Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 230000004899 motility Effects 0.000 claims 3
- 230000017074 necrotic cell death Effects 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 3
- CQDAMYNQINDRQC-UHFFFAOYSA-N oxatriazole Chemical compound C1=NN=NO1 CQDAMYNQINDRQC-UHFFFAOYSA-N 0.000 claims 3
- 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 claims 3
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- 230000000241 respiratory effect Effects 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 claims 3
- YGNGABUJMXJPIJ-UHFFFAOYSA-N thiatriazole Chemical compound C1=NN=NS1 YGNGABUJMXJPIJ-UHFFFAOYSA-N 0.000 claims 3
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 claims 3
- 229930192474 thiophene Natural products 0.000 claims 3
- 230000000451 tissue damage Effects 0.000 claims 3
- 231100000827 tissue damage Toxicity 0.000 claims 3
- 230000009092 tissue dysfunction Effects 0.000 claims 3
- 230000036269 ulceration Effects 0.000 claims 3
- 230000001457 vasomotor Effects 0.000 claims 3
- 208000001319 vasomotor rhinitis Diseases 0.000 claims 3
- 230000009278 visceral effect Effects 0.000 claims 3
- GBLQGXFTPLQBTA-UHFFFAOYSA-N 1,2,3-triazoline Chemical compound C1CN=NN1 GBLQGXFTPLQBTA-UHFFFAOYSA-N 0.000 claims 2
- 125000001401 1,2,4-triazol-4-yl group Chemical group N=1N=C([H])N([*])C=1[H] 0.000 claims 2
- 125000001414 1,2,4-triazol-5-yl group Chemical group [H]N1N=C([H])N=C1[*] 0.000 claims 2
- VBXZSFNZVNDOPB-UHFFFAOYSA-N 1,4,5,6-tetrahydropyrimidine Chemical compound C1CNC=NC1 VBXZSFNZVNDOPB-UHFFFAOYSA-N 0.000 claims 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 2
- APLXYWOZCKOSMG-UHFFFAOYSA-N 3,4-dihydro-2h-1,2,5-thiadiazine Chemical compound C1CN=CSN1 APLXYWOZCKOSMG-UHFFFAOYSA-N 0.000 claims 2
- HMOBRUPKXAKFHS-UHFFFAOYSA-N 4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=CC=C2C(C)(C)CC(=O)NC2=C1 HMOBRUPKXAKFHS-UHFFFAOYSA-N 0.000 claims 2
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 claims 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 2
- CQBVDZLLODTOAS-UHFFFAOYSA-N 4h-1,2,5-thiadiazine Chemical compound C1C=NSC=N1 CQBVDZLLODTOAS-UHFFFAOYSA-N 0.000 claims 2
- RLDJTWKQIMTLEN-UHFFFAOYSA-N 5,6-dihydro-1,4,2-dioxazine Chemical compound C1CON=CO1 RLDJTWKQIMTLEN-UHFFFAOYSA-N 0.000 claims 2
- LUSYNJGQFRRKIA-UHFFFAOYSA-N 5,6-dihydro-2h-1,3-oxazine Chemical compound C1CC=NCO1 LUSYNJGQFRRKIA-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000014181 Bronchial disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- BDURTBMDULENEE-UHFFFAOYSA-N S1NC=CC1.O1NC=CC1 Chemical compound S1NC=CC1.O1NC=CC1 BDURTBMDULENEE-UHFFFAOYSA-N 0.000 claims 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 2
- 208000029162 bladder disease Diseases 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 claims 2
- BIDAKHHAMURWJQ-UHFFFAOYSA-N cyclopenta[b]thiopyran Chemical compound C1=CSC2=CC=CC2=C1 BIDAKHHAMURWJQ-UHFFFAOYSA-N 0.000 claims 2
- WITCGPMUKHXQGW-UHFFFAOYSA-N cyclopenta[c]thiopyran Chemical compound C1=CSC=C2C=CC=C21 WITCGPMUKHXQGW-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 2
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 2
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 2
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims 2
- AYFPGVWCUMGFSR-JLHYYAGUSA-N (3-methoxyphenyl) (e)-3-(4-tert-butylphenyl)prop-2-enoate Chemical compound COC1=CC=CC(OC(=O)\C=C\C=2C=CC(=CC=2)C(C)(C)C)=C1 AYFPGVWCUMGFSR-JLHYYAGUSA-N 0.000 claims 1
- JZPGOILTIFPJPY-FLIBITNWSA-N (Z)-3-(4-tert-butylphenyl)-3-iodoprop-2-enamide Chemical compound C(C)(C)(C)C1=CC=C(C=C1)/C(=C/C(=O)N)/I JZPGOILTIFPJPY-FLIBITNWSA-N 0.000 claims 1
- VGPLGKJGLDHRKC-KPKJPENVSA-N (e)-3-(4-tert-butylphenyl)-n-(1-methylindol-5-yl)prop-2-enamide Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)\C=C\C1=CC=C(C(C)(C)C)C=C1 VGPLGKJGLDHRKC-KPKJPENVSA-N 0.000 claims 1
- WNUQFSSLBYZXJB-IZZDOVSWSA-N (e)-3-(4-tert-butylphenyl)-n-(2,3-dihydro-1h-indol-6-yl)prop-2-enamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=C(CCN2)C2=C1 WNUQFSSLBYZXJB-IZZDOVSWSA-N 0.000 claims 1
- GXKPMXKEYHOACC-MDWZMJQESA-N (e)-3-(4-tert-butylphenyl)-n-(3,4-dimethoxyphenyl)prop-2-enamide Chemical compound C1=C(OC)C(OC)=CC=C1NC(=O)\C=C\C1=CC=C(C(C)(C)C)C=C1 GXKPMXKEYHOACC-MDWZMJQESA-N 0.000 claims 1
- YAJHKMMLZHZIMZ-FMIVXFBMSA-N (e)-3-(4-tert-butylphenyl)-n-(3-hydroxyphenyl)prop-2-enamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=CC(O)=C1 YAJHKMMLZHZIMZ-FMIVXFBMSA-N 0.000 claims 1
- GMSBZMYGYHLZCR-IZZDOVSWSA-N (e)-3-(4-tert-butylphenyl)-n-[1-(2-hydroxyethyl)indol-5-yl]prop-2-enamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=C(N(CCO)C=C2)C2=C1 GMSBZMYGYHLZCR-IZZDOVSWSA-N 0.000 claims 1
- KHKHYEWCOLLFKV-IZZDOVSWSA-N (e)-3-(4-tert-butylphenyl)-n-[1-(2-hydroxyethyl)indol-6-yl]prop-2-enamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=C(C=CN2CCO)C2=C1 KHKHYEWCOLLFKV-IZZDOVSWSA-N 0.000 claims 1
- FDXNOQODXBEQMX-KPKJPENVSA-N (e)-3-(4-tert-butylphenyl)-n-[1-(2-methoxyethyl)indol-5-yl]prop-2-enamide Chemical compound C=1C=C2N(CCOC)C=CC2=CC=1NC(=O)\C=C\C1=CC=C(C(C)(C)C)C=C1 FDXNOQODXBEQMX-KPKJPENVSA-N 0.000 claims 1
- VORXJEYZJGKHJT-KPKJPENVSA-N (e)-3-(4-tert-butylphenyl)-n-[1-(2-methoxyethyl)indol-6-yl]prop-2-enamide Chemical compound C1=C2N(CCOC)C=CC2=CC=C1NC(=O)\C=C\C1=CC=C(C(C)(C)C)C=C1 VORXJEYZJGKHJT-KPKJPENVSA-N 0.000 claims 1
- LKMUYFJTLVTRPL-IZZDOVSWSA-N (e)-3-(4-tert-butylphenyl)-n-[2-(hydroxymethyl)-1h-indol-5-yl]prop-2-enamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=C(NC(CO)=C2)C2=C1 LKMUYFJTLVTRPL-IZZDOVSWSA-N 0.000 claims 1
- OFHMNTWCPPZKHO-FMIVXFBMSA-N (e)-3-(4-tert-butylphenyl)-n-[3-(2-hydroxyethoxy)phenyl]prop-2-enamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=CC(OCCO)=C1 OFHMNTWCPPZKHO-FMIVXFBMSA-N 0.000 claims 1
- NQVKUNVGKKIELF-DTQAZKPQSA-N (e)-3-(4-tert-butylphenyl)-n-[3-[2-(1,3-dioxoisoindol-2-yl)ethoxy]phenyl]prop-2-enamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=CC(OCCN2C(C3=CC=CC=C3C2=O)=O)=C1 NQVKUNVGKKIELF-DTQAZKPQSA-N 0.000 claims 1
- WRGYDQRVDKMWOR-KPKJPENVSA-N (e)-3-(4-tert-butylphenyl)-n-[4-chloro-3-(methylcarbamoylamino)phenyl]prop-2-enamide Chemical compound C1=C(Cl)C(NC(=O)NC)=CC(NC(=O)\C=C\C=2C=CC(=CC=2)C(C)(C)C)=C1 WRGYDQRVDKMWOR-KPKJPENVSA-N 0.000 claims 1
- AVMIAJAOFXDOSN-SDNWHVSQSA-N (e)-3-(4-tert-butylphenyl)-n-phenylprop-2-enamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=CC=C1 AVMIAJAOFXDOSN-SDNWHVSQSA-N 0.000 claims 1
- VHAXLKCWSVBCSH-IZZDOVSWSA-N (e)-3-(4-tert-butylphenyl)-n-quinoxalin-6-ylprop-2-enamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=C(N=CC=N2)C2=C1 VHAXLKCWSVBCSH-IZZDOVSWSA-N 0.000 claims 1
- TZOVPSUEQYGATA-UXBLZVDNSA-N (e)-3-(6-tert-butyl-2-methylpyridin-3-yl)-n-(1h-indol-5-yl)prop-2-enamide Chemical compound CC1=NC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=C(NC=C2)C2=C1 TZOVPSUEQYGATA-UXBLZVDNSA-N 0.000 claims 1
- MMNOSTLHPZKCGI-JXMROGBWSA-N (e)-3-(6-tert-butyl-2-methylpyridin-3-yl)-n-(1h-indol-6-yl)prop-2-enamide Chemical compound CC1=NC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=C(C=CN2)C2=C1 MMNOSTLHPZKCGI-JXMROGBWSA-N 0.000 claims 1
- YCAJIDBYOJYWEZ-UXBLZVDNSA-N (e)-3-(6-tert-butyl-2-methylpyridin-3-yl)-n-[2-(hydroxymethyl)-1h-indol-5-yl]prop-2-enamide Chemical compound CC1=NC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=C(NC(CO)=C2)C2=C1 YCAJIDBYOJYWEZ-UXBLZVDNSA-N 0.000 claims 1
- FFHNKHYNDWLHTE-WEVVVXLNSA-N (e)-3-(6-tert-butylpyridin-3-yl)-n-[1-(2-hydroxyethyl)indol-5-yl]prop-2-enamide Chemical compound C1=NC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=C(N(CCO)C=C2)C2=C1 FFHNKHYNDWLHTE-WEVVVXLNSA-N 0.000 claims 1
- SKBVAGKWEVXLIN-WEVVVXLNSA-N (e)-3-(6-tert-butylpyridin-3-yl)-n-[2-(hydroxymethyl)-1h-indol-5-yl]prop-2-enamide Chemical compound C1=NC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=C(NC(CO)=C2)C2=C1 SKBVAGKWEVXLIN-WEVVVXLNSA-N 0.000 claims 1
- FZXHUTVUNWTZMP-QHHAFSJGSA-N (e)-3-[2,3-difluoro-4-(trifluoromethyl)phenyl]-n-(1h-indol-5-yl)prop-2-enamide Chemical compound FC1=C(F)C(C(F)(F)F)=CC=C1\C=C\C(=O)NC1=CC=C(NC=C2)C2=C1 FZXHUTVUNWTZMP-QHHAFSJGSA-N 0.000 claims 1
- IPSKRGZEAGQLMG-QHHAFSJGSA-N (e)-3-[2,4-bis(trifluoromethyl)phenyl]-n-(1h-indol-5-yl)prop-2-enamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC=C1\C=C\C(=O)NC1=CC=C(NC=C2)C2=C1 IPSKRGZEAGQLMG-QHHAFSJGSA-N 0.000 claims 1
- BKIGDKCEQIACOS-QHHAFSJGSA-N (e)-3-[2-bromo-4-(trifluoromethyl)phenyl]-n-(1h-indol-5-yl)prop-2-enamide Chemical compound BrC1=CC(C(F)(F)F)=CC=C1\C=C\C(=O)NC1=CC=C(NC=C2)C2=C1 BKIGDKCEQIACOS-QHHAFSJGSA-N 0.000 claims 1
- CMVMIBBVNLHAIL-QHHAFSJGSA-N (e)-3-[2-fluoro-4-(trifluoromethyl)phenyl]-n-(1h-indol-5-yl)prop-2-enamide Chemical compound FC1=CC(C(F)(F)F)=CC=C1\C=C\C(=O)NC1=CC=C(NC=C2)C2=C1 CMVMIBBVNLHAIL-QHHAFSJGSA-N 0.000 claims 1
- LXQIGTIFFFDGPE-CSKARUKUSA-N (e)-3-[2-pyridin-3-yl-4-(trifluoromethyl)phenyl]-n-quinolin-3-ylprop-2-enamide Chemical compound C=1C(C(F)(F)F)=CC=C(\C=C\C(=O)NC=2C=C3C=CC=CC3=NC=2)C=1C1=CC=CN=C1 LXQIGTIFFFDGPE-CSKARUKUSA-N 0.000 claims 1
- OOJGFXQKZZZSPW-UXBLZVDNSA-N (e)-n-(1,3-benzothiazol-6-yl)-3-(6-tert-butyl-2-methylpyridin-3-yl)prop-2-enamide Chemical compound CC1=NC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=C(N=CS2)C2=C1 OOJGFXQKZZZSPW-UXBLZVDNSA-N 0.000 claims 1
- QJISURBGYIEJII-QHHAFSJGSA-N (e)-n-(1,3-benzothiazol-6-yl)-3-[2-bromo-4-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound BrC1=CC(C(F)(F)F)=CC=C1\C=C\C(=O)NC1=CC=C(N=CS2)C2=C1 QJISURBGYIEJII-QHHAFSJGSA-N 0.000 claims 1
- DVBPLETXURFYAU-XVNBXDOJSA-N (e)-n-(1,3-benzothiazol-6-yl)-3-[2-methyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)NC1=CC=C(N=CS2)C2=C1 DVBPLETXURFYAU-XVNBXDOJSA-N 0.000 claims 1
- DGOFLKXCPXBMSI-IZZDOVSWSA-N (e)-n-(1-benzofuran-5-yl)-3-(4-tert-butylphenyl)prop-2-enamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=C(OC=C2)C2=C1 DGOFLKXCPXBMSI-IZZDOVSWSA-N 0.000 claims 1
- QEVLOSCWBYWBHN-QHHAFSJGSA-N (e)-n-(1h-indol-5-yl)-3-[2-(1,3-thiazol-2-yl)-4-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound C=1C(C(F)(F)F)=CC=C(\C=C\C(=O)NC=2C=C3C=CNC3=CC=2)C=1C1=NC=CS1 QEVLOSCWBYWBHN-QHHAFSJGSA-N 0.000 claims 1
- WZAQUTXYUVPVIG-FPYGCLRLSA-N (e)-n-(1h-indol-5-yl)-3-[2-(6-methoxypyridin-3-yl)-4-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound C1=NC(OC)=CC=C1C1=CC(C(F)(F)F)=CC=C1\C=C\C(=O)NC1=CC=C(NC=C2)C2=C1 WZAQUTXYUVPVIG-FPYGCLRLSA-N 0.000 claims 1
- CSEIAIYPMGIGIX-XBXARRHUSA-N (e)-n-(1h-indol-5-yl)-3-[2-(pyridin-3-ylmethyl)-4-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound C=1C(C(F)(F)F)=CC=C(\C=C\C(=O)NC=2C=C3C=CNC3=CC=2)C=1CC1=CC=CN=C1 CSEIAIYPMGIGIX-XBXARRHUSA-N 0.000 claims 1
- GNDSXDUVYDUOPT-XVNBXDOJSA-N (e)-n-(1h-indol-5-yl)-3-[2-methyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)NC1=CC=C(NC=C2)C2=C1 GNDSXDUVYDUOPT-XVNBXDOJSA-N 0.000 claims 1
- UFTUBLLKTPZPSI-XBXARRHUSA-N (e)-n-(1h-indol-5-yl)-3-[2-pyridin-3-yl-4-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound C=1C(C(F)(F)F)=CC=C(\C=C\C(=O)NC=2C=C3C=CNC3=CC=2)C=1C1=CC=CN=C1 UFTUBLLKTPZPSI-XBXARRHUSA-N 0.000 claims 1
- QDOOTOIUKPNYNZ-QHHAFSJGSA-N (e)-n-(1h-indol-5-yl)-3-[2-pyridin-4-yl-4-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound C=1C(C(F)(F)F)=CC=C(\C=C\C(=O)NC=2C=C3C=CNC3=CC=2)C=1C1=CC=NC=C1 QDOOTOIUKPNYNZ-QHHAFSJGSA-N 0.000 claims 1
- ZPRONJVVKGEVNX-VMPITWQZSA-N (e)-n-(1h-indol-6-yl)-3-[2-pyridin-3-yl-4-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound C=1C(C(F)(F)F)=CC=C(\C=C\C(=O)NC=2C=C3NC=CC3=CC=2)C=1C1=CC=CN=C1 ZPRONJVVKGEVNX-VMPITWQZSA-N 0.000 claims 1
- YEGPXCDFEQAZBG-FMIVXFBMSA-N (e)-n-[3-(2-aminoethoxy)phenyl]-3-(4-tert-butylphenyl)prop-2-enamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=CC(OCCN)=C1 YEGPXCDFEQAZBG-FMIVXFBMSA-N 0.000 claims 1
- IWPXTELSEHLIJB-FPYGCLRLSA-N (e)-n-[3-(hydroxymethyl)-1,2,3,4-tetrahydroquinolin-7-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound C=1C=C2CC(CO)CNC2=CC=1NC(=O)\C=C\C1=CC=C(C(F)(F)F)C=C1 IWPXTELSEHLIJB-FPYGCLRLSA-N 0.000 claims 1
- JONIAOGHAXHHQR-RUDMXATFSA-N (e)-n-[3-(hydroxymethyl)-1-methyl-3,4-dihydro-2h-quinolin-7-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound C1=C2N(C)CC(CO)CC2=CC=C1NC(=O)\C=C\C1=CC=C(C(F)(F)F)C=C1 JONIAOGHAXHHQR-RUDMXATFSA-N 0.000 claims 1
- MKVBVTOSWPBSNC-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,2,4-triazine Chemical compound C1NNC=CN1 MKVBVTOSWPBSNC-UHFFFAOYSA-N 0.000 claims 1
- LVEKWSMAGKNFCF-UHFFFAOYSA-N 1,2,3,6-tetrahydro-1,2,4-triazine Chemical compound C1NNCN=C1 LVEKWSMAGKNFCF-UHFFFAOYSA-N 0.000 claims 1
- OYEHFRMFJLFNSD-UHFFFAOYSA-N 1,2,5,6-tetrahydro-1,2,4-triazine Chemical compound C1CN=CNN1 OYEHFRMFJLFNSD-UHFFFAOYSA-N 0.000 claims 1
- JPIFWSVAGRPCBJ-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)pyridin-4-yl]phenyl]ethanol Chemical compound C1=CC(C(O)C)=CC=C1C1=CC=NC(NC=2C=C3OCCOC3=CC=2)=C1 JPIFWSVAGRPCBJ-UHFFFAOYSA-N 0.000 claims 1
- OWUQTVMVNCGRLU-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)pyridin-4-yl]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C1=CC=NC(NC=2C=C3OCCOC3=CC=2)=C1 OWUQTVMVNCGRLU-UHFFFAOYSA-N 0.000 claims 1
- HGYGEJZLUZEDIH-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1,2,4-triazine Chemical compound C1NCC=NN1 HGYGEJZLUZEDIH-UHFFFAOYSA-N 0.000 claims 1
- UETXZUQLCCCICD-UHFFFAOYSA-N 2,3-dihydro-1,4,2-oxathiazine Chemical compound C1NOC=CS1 UETXZUQLCCCICD-UHFFFAOYSA-N 0.000 claims 1
- OFJBYLCQNJHFMI-UHFFFAOYSA-N 2,5-dihydro-1,2-oxazole Chemical compound C1ONC=C1 OFJBYLCQNJHFMI-UHFFFAOYSA-N 0.000 claims 1
- UPUWMQZUXFAUCJ-UHFFFAOYSA-N 2,5-dihydro-1,2-thiazole Chemical compound C1SNC=C1 UPUWMQZUXFAUCJ-UHFFFAOYSA-N 0.000 claims 1
- CJUYNKWJWWMLJW-UHFFFAOYSA-N 2,5-dihydrotriazine Chemical compound C1C=NNN=C1 CJUYNKWJWWMLJW-UHFFFAOYSA-N 0.000 claims 1
- PMBTWFPOEZPRBR-UHFFFAOYSA-N 2-(3-methoxyphenoxy)-4-[4-(trifluoromethyl)phenyl]pyridine Chemical compound COC1=CC=CC(OC=2N=CC=C(C=2)C=2C=CC(=CC=2)C(F)(F)F)=C1 PMBTWFPOEZPRBR-UHFFFAOYSA-N 0.000 claims 1
- WQQLIHJGNGRVLL-FMIVXFBMSA-N 2-[3-[[(e)-3-(4-tert-butylphenyl)prop-2-enoyl]amino]phenoxy]acetic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C(=O)NC1=CC=CC(OCC(O)=O)=C1 WQQLIHJGNGRVLL-FMIVXFBMSA-N 0.000 claims 1
- SRCCLYMWDRNUAF-UHFFFAOYSA-N 3,3-dimethyl-1,2-dihydroindole Chemical compound C1=CC=C2C(C)(C)CNC2=C1 SRCCLYMWDRNUAF-UHFFFAOYSA-N 0.000 claims 1
- VGYDMOUMIQOMMU-UHFFFAOYSA-N 3,4-dihydro-2h-1,3-thiazine Chemical compound C1NCC=CS1 VGYDMOUMIQOMMU-UHFFFAOYSA-N 0.000 claims 1
- YEEGQDGJIXWFIQ-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-oxazine Chemical compound C1COC=CN1 YEEGQDGJIXWFIQ-UHFFFAOYSA-N 0.000 claims 1
- NARLFVSETWHKRP-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-thiazine Chemical compound C1CSC=CN1 NARLFVSETWHKRP-UHFFFAOYSA-N 0.000 claims 1
- UAGQYROKNUIGPX-UHFFFAOYSA-N 3,6-dihydro-2h-1,3-thiazine Chemical compound C1NC=CCS1 UAGQYROKNUIGPX-UHFFFAOYSA-N 0.000 claims 1
- RHOMRSNINFNDIY-UHFFFAOYSA-N 3,6-dihydro-2h-1,4-oxazine Chemical compound C1CN=CCO1 RHOMRSNINFNDIY-UHFFFAOYSA-N 0.000 claims 1
- QTAAKTRBARVAQY-UHFFFAOYSA-N 3,6-dihydro-2h-1,4-thiazine Chemical compound C1CN=CCS1 QTAAKTRBARVAQY-UHFFFAOYSA-N 0.000 claims 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 claims 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- AQKLSQTZSACKKL-UHFFFAOYSA-N 4-(1,3-benzodioxol-5-yl)-n-(2,3-dihydro-1,4-benzodioxin-6-yl)pyridin-2-amine Chemical compound O1CCOC2=CC(NC=3N=CC=C(C=3)C3=CC=C4OCOC4=C3)=CC=C21 AQKLSQTZSACKKL-UHFFFAOYSA-N 0.000 claims 1
- CHYOROLLNYULMV-UHFFFAOYSA-N 4-(1-benzothiophen-2-yl)-n-(2,3-dihydro-1,4-benzodioxin-6-yl)pyridin-2-amine Chemical compound C1=CC=C2SC(C=3C=C(N=CC=3)NC=3C=C4OCCOC4=CC=3)=CC2=C1 CHYOROLLNYULMV-UHFFFAOYSA-N 0.000 claims 1
- ZYFWREHXNQYUSE-UHFFFAOYSA-N 4-[3,5-bis(trifluoromethyl)phenyl]-n-(2,3-dihydro-1,4-benzodioxin-6-yl)pyridin-2-amine Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C=2C=C(NC=3C=C4OCCOC4=CC=3)N=CC=2)=C1 ZYFWREHXNQYUSE-UHFFFAOYSA-N 0.000 claims 1
- UDFMGMGVXDBHKD-UHFFFAOYSA-N 4-[4-[4-(trifluoromethyl)phenyl]pyridin-2-yl]oxy-1,3-benzothiazol-2-amine Chemical compound C1=CC=C2SC(N)=NC2=C1OC(N=CC=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 UDFMGMGVXDBHKD-UHFFFAOYSA-N 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- IQOZTIKBIHWYQQ-UHFFFAOYSA-N 4h-1,3-oxazine Chemical compound C1C=COC=N1 IQOZTIKBIHWYQQ-UHFFFAOYSA-N 0.000 claims 1
- NXNZBSJCMSODTO-UHFFFAOYSA-N 5,6-dihydro-2h-1,3-thiazine Chemical compound C1CC=NCS1 NXNZBSJCMSODTO-UHFFFAOYSA-N 0.000 claims 1
- YPXAASDZAZBHMG-UHFFFAOYSA-N 5,6-dihydro-4h-1,3-thiazine Chemical compound C1CSC=NC1 YPXAASDZAZBHMG-UHFFFAOYSA-N 0.000 claims 1
- BXIQUVIVBPUOSD-KPKJPENVSA-N 6-[[(e)-3-(4-tert-butylphenyl)prop-2-enoyl]amino]-n-methylindazole-1-carboxamide Chemical compound C1=C2N(C(=O)NC)N=CC2=CC=C1NC(=O)\C=C\C1=CC=C(C(C)(C)C)C=C1 BXIQUVIVBPUOSD-KPKJPENVSA-N 0.000 claims 1
- MQDXDIVLAQUUPE-UHFFFAOYSA-N 7-[4-[4-(trifluoromethyl)phenyl]pyridin-2-yl]oxyquinoline Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC=NC(OC=2C=C3N=CC=CC3=CC=2)=C1 MQDXDIVLAQUUPE-UHFFFAOYSA-N 0.000 claims 1
- PZLAMTDFMVQHND-UHFFFAOYSA-N 7-tert-butylisoquinoline-3-carboxamide Chemical compound C(C)(C)(C)C1=CC=C2C=C(N=CC2=C1)C(=O)N PZLAMTDFMVQHND-UHFFFAOYSA-N 0.000 claims 1
- RTFYMAQISLJCDS-UHFFFAOYSA-N 8-[4-[4-(trifluoromethyl)phenyl]pyridin-2-yl]oxyquinolin-2-amine Chemical compound C12=NC(N)=CC=C2C=CC=C1OC(N=CC=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 RTFYMAQISLJCDS-UHFFFAOYSA-N 0.000 claims 1
- FLIRHELTVBDESZ-UHFFFAOYSA-N 8-[4-[4-(trifluoromethyl)phenyl]pyridin-2-yl]oxyquinoline Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC=NC(OC=2C3=NC=CC=C3C=CC=2)=C1 FLIRHELTVBDESZ-UHFFFAOYSA-N 0.000 claims 1
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000005824 bladder abnormality Effects 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000004799 bromophenyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- MMUVGZYCOKRPAC-UHFFFAOYSA-N n-(1,3-benzothiazol-6-yl)-3-(4-tert-butylphenyl)-6-imidazol-1-ylhex-2-enamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(CCCN1C=NC=C1)=CC(=O)NC1=CC=C(N=CS2)C2=C1 MMUVGZYCOKRPAC-UHFFFAOYSA-N 0.000 claims 1
- MDZVRJRBFNCVCJ-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(4-fluorophenyl)pyridin-2-amine Chemical compound C1=CC(F)=CC=C1C1=CC=NC(NC=2C=C3OCCOC3=CC=2)=C1 MDZVRJRBFNCVCJ-UHFFFAOYSA-N 0.000 claims 1
- VLKOFKUJZFJHME-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[3-(trifluoromethyl)phenyl]pyridin-2-amine Chemical compound FC(F)(F)C1=CC=CC(C=2C=C(NC=3C=C4OCCOC4=CC=3)N=CC=2)=C1 VLKOFKUJZFJHME-UHFFFAOYSA-N 0.000 claims 1
- AJUSWXYINDCHCJ-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[4-(dimethylamino)phenyl]pyridin-2-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=NC(NC=2C=C3OCCOC3=CC=2)=C1 AJUSWXYINDCHCJ-UHFFFAOYSA-N 0.000 claims 1
- WGYNXWGKWGRADX-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[4-(trifluoromethoxy)phenyl]pyridin-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CC=NC(NC=2C=C3OCCOC3=CC=2)=C1 WGYNXWGKWGRADX-UHFFFAOYSA-N 0.000 claims 1
- SKLVOWLWWJOKFZ-UHFFFAOYSA-N n-[4-[4-[4-(trifluoromethyl)phenyl]pyridin-2-yl]oxy-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=CC=C2SC(NC(=O)C)=NC2=C1OC(N=CC=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 SKLVOWLWWJOKFZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- NCOUFDATAZOQTF-WEVVVXLNSA-N tert-butyl 4-[2-[(e)-3-(1h-indol-5-ylamino)-3-oxoprop-1-enyl]-5-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine-6-carboxylate Chemical compound CC(C)(C)OC(=O)C1NCCC(C=2C(=CC=C(C=2)C(F)(F)F)\C=C\C(=O)NC=2C=C3C=CNC3=CC=2)=C1 NCOUFDATAZOQTF-WEVVVXLNSA-N 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 0 Cc1c(*)c(*)c(*)c(*)c1* Chemical compound Cc1c(*)c(*)c(*)c(*)c1* 0.000 description 11
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33916101P | 2001-12-10 | 2001-12-10 | |
| US34473701P | 2001-12-21 | 2001-12-21 | |
| US38333102P | 2002-05-22 | 2002-05-22 | |
| US40242202P | 2002-08-08 | 2002-08-08 | |
| PCT/US2002/039589 WO2003049702A2 (en) | 2001-12-10 | 2002-12-10 | Vanilloid receptor ligands and their use in treatments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005518371A JP2005518371A (ja) | 2005-06-23 |
| JP2005518371A5 true JP2005518371A5 (https=) | 2006-02-02 |
Family
ID=27502596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003550753A Pending JP2005518371A (ja) | 2001-12-10 | 2002-12-10 | バニロイド受容体リガンド及び治療に於けるこれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US7582657B2 (https=) |
| EP (1) | EP1463714A4 (https=) |
| JP (1) | JP2005518371A (https=) |
| AU (1) | AU2002364549B2 (https=) |
| CA (1) | CA2468544A1 (https=) |
| MX (1) | MXPA04005427A (https=) |
| PL (1) | PL373484A1 (https=) |
| WO (1) | WO2003049702A2 (https=) |
Families Citing this family (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE420644T1 (de) * | 2002-02-20 | 2009-01-15 | Abbott Lab | Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1) |
| WO2003097586A1 (en) | 2002-05-17 | 2003-11-27 | Janssen Pharmaceutica N.V. | Aminotetralin-derived urea modulators of vanilloid vr1 receptor |
| BR0313255A (pt) * | 2002-08-08 | 2005-07-12 | Amgen Inc | Composto, composição farmacêutica, uso de um composto e métodos de fabricar um medicamento e de preparar um composto |
| EP1688408A3 (en) * | 2002-08-08 | 2007-08-22 | Amgen, Inc | Vanilloid receptor ligands and their use in treatments |
| AU2003298567B9 (en) * | 2002-08-29 | 2009-07-23 | Temple University - Of The Commonwealth System Of Higher Education | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof |
| US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
| NZ540381A (en) | 2002-11-01 | 2007-11-30 | Takeda Pharmaceutical | 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy |
| CA2509233A1 (en) * | 2002-12-13 | 2004-07-01 | Neurogen Corporation | 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
| AU2002953533A0 (en) * | 2002-12-24 | 2003-01-16 | Arthron Limited | Fc receptor modulating compounds and compositions |
| US20040192728A1 (en) * | 2003-02-03 | 2004-09-30 | Ellen Codd | Quinoline-derived amide modulators of vanilloid VR1 receptor |
| SE0301446D0 (sv) | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
| CA2531401A1 (en) * | 2003-07-10 | 2005-01-27 | Neurogen Corporation | Substituted heterocyclic diarylamine analogues |
| JP2007523875A (ja) * | 2003-07-15 | 2007-08-23 | ニューロジェン・コーポレーション | バニロイド受容体リガンドとしての置換ピリミジン−４−イルアミン類縁体 |
| CA2531619A1 (en) * | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
| EP1780211A3 (en) * | 2003-09-30 | 2007-06-06 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| AU2004278382B2 (en) * | 2003-09-30 | 2008-09-18 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| WO2005040100A1 (en) * | 2003-10-15 | 2005-05-06 | Bayer Healthcare Ag | Tetrahydro-naphthalene and urea derivatives |
| US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
| DE10360745A1 (de) * | 2003-12-23 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| US7553848B2 (en) | 2004-01-23 | 2009-06-30 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| MY139645A (en) * | 2004-02-11 | 2009-10-30 | Amgen Inc | Vanilloid receptor ligands and their use in treatments |
| JP2007522233A (ja) * | 2004-02-11 | 2007-08-09 | アムジエン・インコーポレーテツド | バニロイド受容体リガンド及び治療におけるそれらの使用 |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US7351739B2 (en) * | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
| MY149038A (en) * | 2004-05-26 | 2013-07-15 | Eisai R&D Man Co Ltd | Cinnamide compound |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| RS56037B1 (sr) | 2004-06-24 | 2017-09-29 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
| EP1775283A4 (en) * | 2004-07-14 | 2008-12-10 | Japan Tobacco Inc | 3-AMINOBENZAMIDE COMPOUND AND INHIBITORS OF THE ACTIVITY OF VANILLOID RECEPTOR 1 (VR1) |
| KR101042490B1 (ko) | 2004-07-15 | 2011-06-16 | 니뽄 다바코 산교 가부시키가이샤 | 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(ｖｒ1)활성 저해제 |
| FR2874015B1 (fr) | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| CA2580119A1 (en) * | 2004-10-26 | 2006-05-04 | Eisai R & D Management Co., Ltd. | Amorphous object of cinnamide compound |
| MX2007007226A (es) | 2004-12-17 | 2007-08-21 | Lilly Co Eli | Antagonistas receptores novedosos de hormona concentradora de melanina (mch). |
| WO2006089311A1 (en) * | 2005-02-15 | 2006-08-24 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| KR101304981B1 (ko) | 2005-03-19 | 2013-09-06 | (주)아모레퍼시픽 | 바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물 |
| US20060223837A1 (en) * | 2005-03-24 | 2006-10-05 | Ellen Codd | Biaryl derived amide modulators of vanilloid VR1 receptor |
| RU2451014C2 (ru) * | 2005-07-22 | 2012-05-20 | Мотида Фармасьютикал Ко., Лтд. | Новое производное гетероциклиден ацетамида |
| JP4754566B2 (ja) | 2005-07-22 | 2011-08-24 | 持田製薬株式会社 | 新規なヘテロシクリデンアセトアミド誘導体 |
| JP2009514876A (ja) * | 2005-11-03 | 2009-04-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼのための化合物および組成物 |
| AU2006316005A1 (en) * | 2005-11-18 | 2007-05-24 | Eisai R & D Management Co., Ltd. | Process for production of cinnamamide derivative |
| EP1953151A4 (en) * | 2005-11-18 | 2010-06-02 | Eisai R&D Man Co Ltd | SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF |
| RU2381225C1 (ru) * | 2005-11-24 | 2010-02-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Производное циннамида типа морфолина |
| TWI370130B (en) * | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
| WO2007076104A1 (en) * | 2005-12-23 | 2007-07-05 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| TW200736227A (en) | 2005-12-23 | 2007-10-01 | Astrazeneca Ab | New compounds III |
| EP1979367A2 (en) * | 2005-12-24 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Quinolin-4-one derivatives as modulators of abc transporters |
| CA2632508A1 (en) * | 2005-12-28 | 2008-06-05 | Japan Tobacco Inc. | 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (vr1) activity |
| US7906508B2 (en) * | 2005-12-28 | 2011-03-15 | Japan Tobacco Inc. | 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity |
| EP3219705B1 (en) | 2005-12-28 | 2020-03-11 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| TWI378091B (en) * | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
| CA2652484A1 (en) * | 2006-05-19 | 2007-11-29 | Eisai R & D Management Co., Ltd. | Heterocyclic type cinnamide derivative |
| DK2035369T3 (da) | 2006-07-05 | 2014-10-06 | Fibrotech Therapeutics Pty Ltd | Terapeutiske |
| EP1889830A1 (en) | 2006-07-10 | 2008-02-20 | Pharmeste S.r.l. | Biarylcarboxyarylamides as vanilloid-1 receptor modulators |
| EP1889837A1 (en) * | 2006-07-10 | 2008-02-20 | Pharmeste S.r.l. | VR1 vanilloid receptor antagonists with a iononic substructure |
| EP2050734A1 (en) | 2006-07-13 | 2009-04-22 | Kyowa Hakko Kirin Co., Ltd. | Pentadienamide derivative |
| PL2054411T3 (pl) | 2006-07-27 | 2015-02-27 | Amorepacific Corp | Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne |
| AR062095A1 (es) | 2006-07-28 | 2008-10-15 | Eisai R&D Man Co Ltd | Profarmaco de compuesto cinamida |
| US8034940B2 (en) | 2006-08-09 | 2011-10-11 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
| TW200824687A (en) | 2006-08-25 | 2008-06-16 | Abbott Lab | Compounds that inhibit TRPV1 and uses thereof |
| US20080095720A1 (en) * | 2006-10-18 | 2008-04-24 | Conopco, Inc., D/B/A Unilever | Skin Benefit Compositions with a Vanilloid Receptor Antagonist |
| EP1939181A1 (en) * | 2006-12-27 | 2008-07-02 | sanofi-aventis | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase |
| FR2911604B1 (fr) | 2007-01-19 | 2009-04-17 | Sanofi Aventis Sa | Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2911605B1 (fr) | 2007-01-19 | 2009-04-17 | Sanofi Aventis Sa | Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique |
| PE20081692A1 (es) * | 2007-01-24 | 2008-12-18 | Mochida Pharm Co Ltd | Nuevo derivado de heterocicliden acetamida |
| CL2008000582A1 (es) * | 2007-02-28 | 2008-06-27 | Eisai R&D Man Co Ltd | Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis. |
| ITFI20070097A1 (it) * | 2007-04-20 | 2008-10-21 | Antonio Guarna | Molecole eterocicliche contenenti il nucleo della morfolina loro preparazione ed uso. |
| WO2008140111A1 (ja) * | 2007-05-16 | 2008-11-20 | Eisai R & D Management Co., Ltd. | シンナミド誘導体のワンポット製造方法 |
| WO2009001374A2 (en) * | 2007-06-25 | 2008-12-31 | Aptuit Laurus Pvt Ltd | Preparation of ethyl-3'-[((7-chloro-2-quinolinyl)ethenyl)phenyl]-3-oxopropanoate, a key intermediate for montelukast sodium |
| WO2009023160A2 (en) * | 2007-08-11 | 2009-02-19 | The Uab Research Foundation | Novel inhibitors of bacterial sortase enzymes and methods of using the same |
| US7935815B2 (en) * | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
| ES2529648T3 (es) | 2007-08-31 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Compuesto policíclico |
| WO2009079692A1 (en) | 2007-12-21 | 2009-07-02 | Fibrotech Therapeutics Pty Ltd | Halogenated analogues of anti-fibrotic agents |
| US20110207987A1 (en) * | 2009-11-02 | 2011-08-25 | Salutaris Medical Devices, Inc. | Methods And Devices For Delivering Appropriate Minimally-Invasive Extraocular Radiation |
| DK2227257T3 (da) | 2008-01-07 | 2013-09-30 | Salutaris Medical Devices Inc | Anordninger til minimal-invasiv ekstraokular afgivelse af stråling til den posteriore del af øjet |
| US10022558B1 (en) | 2008-01-07 | 2018-07-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US8608632B1 (en) | 2009-07-03 | 2013-12-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye |
| US8602959B1 (en) | 2010-05-21 | 2013-12-10 | Robert Park | Methods and devices for delivery of radiation to the posterior portion of the eye |
| US9056201B1 (en) | 2008-01-07 | 2015-06-16 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US9873001B2 (en) | 2008-01-07 | 2018-01-23 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US20100317860A1 (en) * | 2008-01-28 | 2010-12-16 | Ikuo Kushida | Crystalline cinnamide compounds or salts thereof |
| US8557872B2 (en) | 2008-01-28 | 2013-10-15 | Amorepacific Corporation | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| KR20130097813A (ko) | 2008-04-21 | 2013-09-03 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
| US8691855B2 (en) | 2008-07-02 | 2014-04-08 | Amorepacific Corporation | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same |
| JP5421366B2 (ja) | 2008-07-21 | 2014-02-19 | オトノミ―，インク． | 制御放出性の耳の構造体調節および生来の免疫システム調節化合物および耳の障害の処置のための方法 |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| EP2349263B1 (en) | 2008-10-23 | 2014-04-23 | Vertex Pharmaceuticals Inc. | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP2179984A1 (en) | 2008-10-27 | 2010-04-28 | Congenia S.r.l. | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition |
| USD691268S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| USD691267S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| USD691270S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| USD691269S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| TWI402250B (zh) * | 2009-02-03 | 2013-07-21 | Nippon Soda Co | Phenolic compounds and recording materials |
| WO2010089982A1 (ja) * | 2009-02-03 | 2010-08-12 | 日本曹達株式会社 | リライタブル記録材料 |
| PL2408750T3 (pl) | 2009-03-20 | 2016-02-29 | Vertex Pharma | Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy |
| EP2491030B1 (en) | 2009-10-22 | 2015-07-15 | Fibrotech Therapeutics PTY LTD | Fused ring analogues of anti-fibrotic agents |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| AU2011308256B2 (en) * | 2010-09-28 | 2015-08-20 | Daewoong Pharmaceutical Co., Ltd. | Novel method of preparing benzoimidazole derivatives |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| JP2015511583A (ja) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的組成物およびその投与 |
| US20150225369A1 (en) * | 2012-08-29 | 2015-08-13 | Merck Patent Gmbh | Ddr2 inhibitors for the treatment of osteoarthritis |
| HK1214587A1 (en) | 2012-12-28 | 2016-07-29 | Nippon Zoki Pharmaceutical Co., Ltd. | Cinnamamide derivative |
| FR3006192A1 (fr) * | 2013-05-30 | 2014-12-05 | Centre Nat Rech Scient | Composes de type phenyle propenamide pour leur utilisation en tant que medicament |
| SI3004138T1 (sl) | 2013-06-05 | 2024-07-31 | Bausch Health Ireland Limited | Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| WO2016077240A2 (en) | 2014-11-10 | 2016-05-19 | Forge Life Science, Llc | Anti-hcmv compositions and methods |
| JP2018512436A (ja) * | 2015-04-15 | 2018-05-17 | バレント・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＶａｌｅｎｔ ＢｉｏＳｃｉｅｎｃｅｓ ＬＬＣ | （ｓ）−２’−ビニル−アブシジン酸誘導体 |
| KR102439852B1 (ko) * | 2015-04-17 | 2022-09-05 | 가천대학교 산학협력단 | 2-아미노퀴놀린-8-올 유도체, 및 이의 용도 |
| KR101806485B1 (ko) | 2015-09-04 | 2017-12-08 | 서울대학교산학협력단 | 파이퍼 아마이드 유도체를 포함하는 피부 미백용 조성물 |
| CN105130964A (zh) * | 2015-09-28 | 2015-12-09 | 侯方杰 | 一种可用于制备治疗心血管疾病药物的化合物及其制备方法、用途 |
| CN105153125A (zh) * | 2015-09-29 | 2015-12-16 | 青岛友诚高新技术有限公司 | 一种可用于制备保护心肌缺血药物的化合物及其制备方法、用途 |
| CN105085492A (zh) * | 2015-09-29 | 2015-11-25 | 青岛友诚高新技术有限公司 | 一种可用于制备治疗冠状动脉粥样硬化药物的化合物及其制备方法、用途 |
| CN105130965A (zh) * | 2015-10-08 | 2015-12-09 | 侯方杰 | 一种可用于制备治疗心血管疾病药物的化合物及其制备方法、用途 |
| CN105461700A (zh) * | 2015-12-02 | 2016-04-06 | 青岛市中心医院 | 一种可用于制备抗乳腺癌药物的化合物及其制备方法、用途 |
| WO2017102014A1 (en) * | 2015-12-17 | 2017-06-22 | Universite D'aix-Marseille | Propenamide thiophene derivatives as flavivirus inhibitors and their use |
| USD814638S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD814637S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD815285S1 (en) | 2016-05-11 | 2018-04-10 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| JP7033789B2 (ja) | 2016-06-29 | 2022-03-11 | オトノミー，インク． | トリグリセリド耳用製剤とその使用 |
| USD808528S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| USD808529S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| WO2018101793A2 (ko) * | 2016-12-01 | 2018-06-07 | 서울대학교 산학협력단 | 아미드 유도체 화합물, 이의 입체이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 포함하는 피부 노화 억제, 주름 개선, 또는 피부 상처 치료용 약학적 또는 화장료 조성물 |
| ES2901617T3 (es) * | 2016-12-14 | 2022-03-23 | Glaxosmithkline Ip Dev Ltd | Bisarilamidas como reguladores de NRF2 |
| CA3052036A1 (en) | 2017-02-03 | 2018-08-09 | Certa Therapeutics Pty Ltd. | Anti-fibrotic compounds |
| WO2019084338A1 (en) | 2017-10-25 | 2019-05-02 | University Of South Florida | DRUG-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM |
| KR102334947B1 (ko) * | 2020-04-22 | 2021-12-06 | 주식회사 제이맥켐 | Trpv1 길항제로서 벤즈이미다졸론계 시남아마이드 유도체 및 이를 유효성분으로 함유하는 통증의 치료 또는 예방용 약학적 조성물 |
| CN113549018B (zh) * | 2020-04-24 | 2024-02-27 | 中国药科大学 | 蛋白激酶抑制剂及其衍生物，制备方法、药物组合物和应用 |
| DE102022104759A1 (de) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen |
| WO2024206284A2 (en) * | 2023-03-27 | 2024-10-03 | Rutgers, The State University Of New Jersey | Therapeutic compounds |
| CN120398870A (zh) * | 2024-01-31 | 2025-08-01 | 深圳晶蛋生物医药科技有限公司 | 一种苯并吗啉类化合物及其应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US456346A (en) * | 1891-07-21 | Henry e | ||
| US87922A (en) * | 1869-03-16 | Improvement in gas-burners | ||
| US4011236A (en) | 1968-09-09 | 1977-03-08 | Merck & Co., Inc. | N-(benzimidazol-2-yl)arylcarboxamides as ultraviolet (uv) light absorbers |
| US3853561A (en) * | 1970-11-26 | 1974-12-10 | Hoechst Ag | Process for the preparation of screen printing stencils using intermediate support for light sensitive layer |
| JPS5640710B2 (https=) | 1973-01-18 | 1981-09-22 | ||
| FR2230764B1 (https=) * | 1973-05-21 | 1977-02-11 | Verdol Sa | |
| CS244440B2 (en) * | 1983-02-28 | 1986-07-17 | Celamerck Gmbh & Co Kg | Method of acrylic acids' new amides production |
| US4536346A (en) | 1983-05-06 | 1985-08-20 | American Cyanamid Company | Aralkanamidophenyl compounds |
| FR2559763B1 (fr) | 1984-02-22 | 1986-07-11 | Centre Nat Rech Scient | Composes possedant, notamment, des proprietes inhibitrices vis-a-vis de la lignification dans les vegetaux et procede pour la reduction de leur taux de lignine |
| JPH064584B2 (ja) | 1984-02-29 | 1994-01-19 | 沢井製薬株式会社 | 新規アニリド誘導体 |
| CA1261835A (en) | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
| JPH0723349B2 (ja) * | 1986-12-17 | 1995-03-15 | 鐘淵化学工業株式会社 | ３，５−ジ−タ−シヤリ−ブチル−４−ヒドロキシケイ皮酸アミド誘導体 |
| US4927838A (en) | 1987-07-10 | 1990-05-22 | Hoffman-La Roche Inc. | Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors |
| DE3803775A1 (de) | 1988-02-09 | 1989-08-17 | Boehringer Mannheim Gmbh | Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
| US4908381A (en) | 1988-12-05 | 1990-03-13 | Ecolab Inc. | Antimicrobial film-forming compositions |
| US5143919A (en) | 1990-08-17 | 1992-09-01 | Takeda Chemical Industries, Ltd. | Thienopyridine derivatives and their pharmaceutical use |
| DE69216873T2 (de) | 1991-02-21 | 1997-08-21 | Sankyo Co | Benzolderivate zum Fördern der Produktion des Nervenwachstumsfaktors |
| GB9208492D0 (en) | 1992-04-16 | 1992-06-03 | Glaxo Spa | Heterocyclic compounds |
| US5453421A (en) | 1992-09-11 | 1995-09-26 | E. R. Squibb & Sons, Inc. | Aryl and heterocyclic substituted propenamide derivatives |
| JPH06179660A (ja) | 1992-10-14 | 1994-06-28 | Nippon Soda Co Ltd | ジシアノピラジン誘導体 |
| US5731324A (en) | 1993-07-22 | 1998-03-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
| GB9319243D0 (en) | 1993-09-17 | 1993-11-03 | Glaxo Spa | Heterocyclic compounds |
| GB9504361D0 (en) | 1995-03-04 | 1995-04-26 | Glaxo Spa | Heterocyclic compounds |
| IL118469A (en) * | 1995-06-15 | 2000-08-13 | Tanabe Seiyaku Co | Naphthalene derivatives their preparation and intermediates thereof |
| US5780487A (en) * | 1995-08-07 | 1998-07-14 | Amer Moh Samir | S-2'- 2-(1-methyl-2-piperidyl) ethyl! cinnamanilide |
| US5731342A (en) * | 1996-02-22 | 1998-03-24 | Eli Lilly And Company | Benzothiophenes, formulations containing same, and methods |
| AU2652397A (en) | 1996-05-13 | 1997-12-05 | Nippon Shinyaku Co. Ltd. | Substituted ethylene compounds and drugs |
| US5776930A (en) | 1996-06-28 | 1998-07-07 | Merck & Company, Inc. | Pharmaceutical preparation |
| US5919776A (en) | 1996-12-20 | 1999-07-06 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
| NZ507032A (en) | 1998-03-19 | 2003-06-30 | Pharmacia & Upjohn | 1,3,4-thiadiazoles useful for the treatment of herpes and cytomegalovirus infections |
| CA2338804A1 (en) | 1998-07-28 | 2000-02-10 | Smithkline Beecham Corporation | Propenamides as ccr5 modulators |
| GB9816984D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Plc | Novel compounds |
| AU1707700A (en) | 1998-10-29 | 2000-05-22 | Bristol-Myers Squibb Company | Novel inhibitors of impdh enzyme |
| DE19935219A1 (de) | 1999-07-27 | 2001-02-01 | Boehringer Ingelheim Pharma | Carbonsäureamide, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
| MXPA02001565A (es) * | 1999-08-13 | 2005-07-14 | Vertex Pharma | Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas. |
| EP1218336A2 (en) | 1999-09-20 | 2002-07-03 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| EP1268484A1 (en) | 2000-03-17 | 2003-01-02 | Novo Nordisk A/S | Condensed imidazoles as histamine h3 receptor ligands |
| GB0014022D0 (en) * | 2000-06-08 | 2000-08-02 | Novartis Ag | Organic compounds |
| US20030232860A1 (en) * | 2000-07-18 | 2003-12-18 | Hironori Harada | Medicine comprising dicyanopyridine derivative |
| EP1373257B9 (en) | 2001-03-29 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| AU2002352868A1 (en) | 2001-11-27 | 2003-06-10 | Merck & Co., Inc. | 4-aminoquinoline compounds |
| GB0226724D0 (en) | 2002-11-15 | 2002-12-24 | Merck Sharp & Dohme | Therapeutic agents |
-
2002
- 2002-12-10 MX MXPA04005427A patent/MXPA04005427A/es active IP Right Grant
- 2002-12-10 PL PL02373484A patent/PL373484A1/xx unknown
- 2002-12-10 EP EP02799927A patent/EP1463714A4/en not_active Withdrawn
- 2002-12-10 CA CA002468544A patent/CA2468544A1/en not_active Abandoned
- 2002-12-10 WO PCT/US2002/039589 patent/WO2003049702A2/en not_active Ceased
- 2002-12-10 US US10/316,295 patent/US7582657B2/en not_active Expired - Fee Related
- 2002-12-10 AU AU2002364549A patent/AU2002364549B2/en not_active Ceased
- 2002-12-10 JP JP2003550753A patent/JP2005518371A/ja active Pending
-
2005
- 2005-04-05 US US11/099,978 patent/US20050272931A1/en not_active Abandoned
- 2005-04-05 US US11/100,077 patent/US7579347B2/en not_active Expired - Fee Related
- 2005-04-05 US US11/100,272 patent/US20060030618A1/en not_active Abandoned
-
2009
- 2009-06-26 US US12/492,376 patent/US20090264424A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005518371A5 (https=) | ||
| JP2005531574A5 (https=) | ||
| JP2005518371A (ja) | バニロイド受容体リガンド及び治療に於けるこれらの使用 | |
| CA2493667A1 (en) | Vanilloid receptor ligands and their use in treatments | |
| WO2003099284B1 (en) | Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain | |
| TWI404715B (zh) | 二芳基醚脲化合物 | |
| JP2007533635A (ja) | バニロイド受容体リガンドおよび治療おけるこれらの使用 | |
| JP4216196B2 (ja) | Ｎｐｙアンタゴニストとしてのキノリン誘導体 | |
| JP2006519264A (ja) | 癌および他の障害の処置に有用な新規シアノピリジン誘導体 | |
| HUP0401898A2 (hu) | 3-Szubsztituált-4-pirimidon-származékok, ezeket tartalmazó gyógyászati készítmények és intermedierjeik | |
| CZ2003765A3 (cs) | Deriváty chinazolinu jako inhibitory kinázy | |
| BG63487B1 (bg) | Използване на хетероциклени съединения | |
| CN103429583A (zh) | 作为wnt信号通路抑制剂的三唑衍生物 | |
| HU191092B (en) | Process for producing 1,4-dihydro-pyridine derivatives | |
| JPH09511759A (ja) | アポリポタンパク質−ｂ合成阻害剤 | |
| BRPI0709101A2 (pt) | derivados de triazolona e medicamento e agente terapêutico e/ou profilático compreendendo os mesmos | |
| JP5372138B2 (ja) | 新規ベンゾオキサジンベンズイミダゾール誘導体、これを含む薬学組成物およびこの用途 | |
| WO2012174856A1 (zh) | 一类可用于口服的凝血酶抑制剂及其制法以及医药用途 | |
| JPH05194441A (ja) | 新規な置換３−ピペラジニルアルキル−２，３−ジヒドロ−４ｈ−１，３−ベンゾオキサジン−４−オン、その製造法および治療用途 | |
| JP4662979B2 (ja) | 新規なβ−アゴニスト、その製造方法及びその薬物としての使用 | |
| WO2010111948A1 (zh) | 芳甲胺类化合物、其制备方法及其医药用途 | |
| JPS6344576A (ja) | 新規ピリダジノン誘導体、それらの製造方法並びに医薬としてのそれらの利用法 | |
| AU2009221294A1 (en) | 2-Aminoquinolines | |
| WO2010141550A2 (en) | 11-beta hsd1 inhibitors | |
| JP2007537225A (ja) | ５−ｈｔ７活性剤としてのアルキルオキシインドールのピリジン誘導体 |